

Monographs@FDA portal at <https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm>, to the extent the corresponding deemed final order has been added to the portal. Additionally, in either the same notice or a separate notice in the **Federal Register**, pursuant to section 505G(k)(3) of the FD&C Act, FDA intends to withdraw certain portions of the regulations governing the OTC drug review, and to make certain technical changes.

**IV. Paperwork Reduction Act of 1995**

Under section 505G(o) of the FD&C Act, the Paperwork Reduction Act of 1995 (Chapter 35 of title 44, United States Code) does not apply to collections of information made under section 505G of the FD&C Act. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required for collections of information, if any, in orders deemed to be final orders by section 505G of the FD&C Act.

Dated: September 16, 2021.

**Lauren K. Roth,**

*Acting Principal Associate Commissioner for Policy.*

[FR Doc. 2021-20393 Filed 9-20-21; 8:45 am]

**BILLING CODE 4164-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

[Document Identifier: OS-0990-0281]

**Agency Father Generic Information Collection Request; 30-Day Public Comment Request**

**AGENCY:** Office of the Secretary, Health and Human Service, HHS.

**ACTION:** Notice and request for comments.

**SUMMARY:** In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.

**DATES:** Comments on the ICR must be received on or before October 21, 2021.

**ADDRESSES:** Submit your comments to [OIRA\\_submission@omb.eop.gov](mailto:OIRA_submission@omb.eop.gov) or via facsimile to (202) 395-5806.

**FOR FURTHER INFORMATION CONTACT:** Sherrette Funn, [Sherrette.Funn@hhs.gov](mailto:Sherrette.Funn@hhs.gov) or (202) 795-7714. When requesting information, please include the document identifier 0990-0281-30D and project title for reference.

**SUPPLEMENTARY INFORMATION:** Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

*Title of the Collection:* Prevention Communication Formative Research.

*Type of Collection:* Extension.

*OMB No.:* 0990-0281—Office of Disease Prevention and Health Promotion.

*Abstract:* The Office of Disease Prevention and Health Promotion (ODPHP) is focused on developing and disseminating health information to the public. ODPHP faces an increasingly urgent interest in finding effective ways to communicate health information to America's diverse population. ODPHP

strives to be responsive to the needs of America's diverse audiences while simultaneously serving all Americans across a range of channels, from print to new communication technologies. To carry out prevention information efforts, ODPHP is committed to conducting formative and usability research to provide guidance on the development and implementation of their communication and education efforts. The information collected will be used to improve communication, products, and services that support key office activities including: Healthy People, Dietary Guidelines for Americans, Physical Activity Guidelines for Americans, MyHealthfinder, the Move Your Way® Campaign, the President's Council on Sports, Fitness & Nutrition, health literacy and healthy aging. ODPHP communicates through its websites ([www.health.gov](http://www.health.gov)) and through other channels including social media, print materials, interactive training modules, and reports. This request builds on previous formative research approaches to place more emphasis on Web-based data collection to allow greater geographical diversity among respondents, to decrease respondent burden, and to save government costs. Data collection will be qualitative and quantitative and may include in-depth interviews, focus groups, web-based surveys, omnibus surveys, card sorting, and various forms of usability testing of materials and interactive tools to assess the public's understanding of disease prevention and health promotion content, responses to prototype materials, and barriers to effective use. The program is requesting a 3-year clearance. The type of respondents are consumers and health professionals which will be surveyed on an annual basis.

**ESTIMATED ANNUALIZED BURDEN TABLE**

Type of respondent	Number of respondents	Number responses per respondent	Average burden per response (in hours)	Total burden hours
Consumers (screening & omnibus survey) .....	7725	1	10/60	1287.5
Consumers (qualitative testing) .....	1250	1	1	1250
Consumers (focus groups) .....	575	1	1.5	862.5
Consumers (screening & intercepts) .....	35250	1	5/60	2937.5
Consumers (survey) .....	10000	1	15/60	2500
Consumers (gatekeeper reviews) .....	325	1	30/60	162.5
Consumers (cognitive tests) .....	50	1	2	100
Health care professionals (screening) .....	1350	1	10/60	225
Health care professionals (interview) .....	50	1	1	50
Health care professionals (focus group) .....	400	1	1.5	600
<b>Total</b> .....				<b>9,975</b>

Sherrette A. Funn,

*Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary.*

[FR Doc. 2021–20324 Filed 9–20–21; 8:45 am]

BILLING CODE 4150–32–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Tropical Medicine Research Centers (U01 Clinical Trial Not Allowed).

*Date:* October 18–19, 2021.

*Time:* 10:00 a.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G62A, Rockville, MD 20892 (Virtual Meeting).

*Contact Person:* Eleazar Cohen, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G62A, Rockville, MD 20852, (240) 669–5081, [ecohen@niaid.nih.gov](mailto:ecohen@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: September 15, 2021.

**Tyeshia M. Roberson-Curtis,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021–20370 Filed 9–20–21; 8:45 am]

BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the NIH Clinical Center Research Hospital Board.

The meeting will be held as a virtual meeting and open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH video <https://videocast.nih.gov/> and the CCRHB website <https://ccrhb.od.nih.gov/meetings.html>.

*Name of Committee:* NIH Clinical Center Research Hospital Board.

*Date:* October 15, 2021.

*Time:* 9:00 a.m. to 1:00 p.m.

*Agenda:* CC CEO Update, Patient Safety and Clinical Quality Update, other business of the Board.

*Place:* National Institutes of Health, Building 1, 9000 Rockville Pike, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Gretchen Wood, Staff Assistant, National Institutes of Health, Office of the Director, One Center Drive, Building 1, Room 126, Bethesda, MD 20892, 301–496–4272, [woodgs@od.nih.gov](mailto:woodgs@od.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: September 15, 2021.

**Patricia B. Hansberger,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021–20369 Filed 9–20–21; 8:45 am]

BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Mental Health (NIMH); Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Interagency Autism Coordinating Committee.

The purpose of the IACC meeting is to discuss business, agency updates, and issues related to autism spectrum disorder (ASD) research and services activities. The meeting will be held as a virtual meeting and is open to the public. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting should notify the Contact Person listed below at least seven (7) business days in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocast website (<http://videocast.nih.gov/>).

*Name of Committee:* Interagency Autism Coordinating Committee (IACC).

*Date:* October 13–14, 2021 Meeting schedule subject to change.

*Time:* 1:00 p.m. to 5:00 p.m.

*Meeting Access:* Wednesday, October 13, 2021 <https://videocast.nih.gov/watch=42377> Thursday, October 14, 2021 <https://videocast.nih.gov/watch=42378>.

*Agenda:* To discuss business, updates, and issues related to ASD research and services activities.

*Cost:* The meeting is free and open to the public.

*Registration:* A registration web link will be posted on the IACC website ([www.iacc.hhs.gov](http://www.iacc.hhs.gov)) prior to the meeting. Pre-registration is recommended.

*Deadlines:* Written/Virtual Public Comment Due *Date:* Friday, October 1, 2021, by 5:00 p.m. ET. For instructions, see below.

*Contact Person:* Ms. Rebecca Martin, Office of Autism Research Coordination, National Institute of Mental Health, NIH, 6001 Executive Boulevard, Bethesda, MD 20892–9669, Phone: 301–435–0886, Email: [IACCPublicInquiries@mail.nih.gov](mailto:IACCPublicInquiries@mail.nih.gov).

#### Public Comments

The IACC welcomes public comments from members of the autism community. As the IACC will be updating its Strategic Plan, comments related to issues that the community would like to see highlighted in the new IACC Strategic Plan are welcome. Comments may be submitted in writing via email to [IACCPublicInquiries@mail.nih.gov](mailto:IACCPublicInquiries@mail.nih.gov) or using the web form at: <https://iacc.hhs.gov/meetings/public-comments/submit/index.jsp> by 5:00 p.m. ET on Friday, October 1, 2021. A limited number of slots are available for